Recombinant multi-species IL-27/IL-27A/IL27 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine IL-27/IL-27A/IL27 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
The protein encoded by this gene is one of the subunits of a heterodimeric cytokine complex. This protein is related to interleukin 12A (IL12A). It interacts with Epstein-Barr virus induced gene 3 (EBI3), a protein similar to interleukin 12B (IL12B), and forms a complex that has been shown to drive rapid expansion of naive but not memory CD4(+) T cells. The complex is also found to synergize strongly with interleukin 12 to trigger interferon gamma (IFNG) production of naive CD4(+) T cells. The biological effects of this cytokine are mediated by the class I cytokine receptor (WSX1/TCRR). [provided by RefSeq, Jul 2008]
The Alternative Names of target: IL-27,IL-27 subunit alpha,IL-27-A,IL-27A,IL-27alpha,IL-27p28,IL27,IL27-A,IL27A,IL27p28,IL30,Il27,Il30,Interleukin-27 subunit alpha,Interleukin-30,RGD1561420,p28

Target products collectionGo to IL-27/IL-27A/IL27 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-SE1026-Ag-1/ GM-Tg-hg-SE1026-Ag-2 Human IL-27/IL-27A/IL27 protein Human
GM-Tg-rg-SE1026-Ag-1/ GM-Tg-rg-SE1026-Ag-2 Rat IL-27/IL-27A/IL27 protein Rat
GM-Tg-mg-SE1026-Ag-1/ GM-Tg-mg-SE1026-Ag-2 Mouse IL-27/IL-27A/IL27 protein Mouse
GM-Tg-cynog-SE1026-Ag-1/ GM-Tg-cynog-SE1026-Ag-2 Cynomolgus/Rhesus macaque IL-27/IL-27A/IL27 protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-SE1026-Ag-1/ GM-Tg-felg-SE1026-Ag-2 Feline IL-27/IL-27A/IL27 protein Feline
GM-Tg-cang-SE1026-Ag-1/ GM-Tg-cang-SE1026-Ag-2 Canine IL-27/IL-27A/IL27 protein Canine
GM-Tg-bovg-SE1026-Ag-1/ GM-Tg-bovg-SE1026-Ag-2 Bovine IL-27/IL-27A/IL27 protein Bovine
GM-Tg-equg-SE1026-Ag-1/ GM-Tg-equg-SE1026-Ag-2 Equine IL-27/IL-27A/IL27 protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-SE1026-Ag-1/ GM-Tg-hg-SE1026-Ag-2; GM-Tg-rg-SE1026-Ag-1/ GM-Tg-rg-SE1026-Ag-2;
GM-Tg-mg-SE1026-Ag-1/ GM-Tg-mg-SE1026-Ag-2; GM-Tg-cynog-SE1026-Ag-1/ GM-Tg-cynog-SE1026-Ag-2;
GM-Tg-felg-SE1026-Ag-1/ GM-Tg-felg-SE1026-Ag-2; GM-Tg-cang-SE1026-Ag-1/ GM-Tg-cang-SE1026-Ag-2;
GM-Tg-bovg-SE1026-Ag-1/ GM-Tg-bovg-SE1026-Ag-2; GM-Tg-equg-SE1026-Ag-1/ GM-Tg-equg-SE1026-Ag-2
Products Name IL-27/IL-27A/IL27 protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name IL-27/IL-27A/IL27
Protein Sub-location Secreted Protein/Potential Cytokines
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine IL-27/IL-27A/IL27 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.